Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )

AIMS: Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effects of dapagliflozin were examined according to bod...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamson, Carly, Kondo, Toru, Jhund, Pardeep S, de Boer, Rudolf A, Cabrera Honorio, Jose Walter, Claggett, Brian, Desai, Akshay S, Alcocer Gamba, Marco Antonio, Al Habeeb, Waleed, Hernandez, Adrian F, Inzucchi, Silvio E, Kosiborod, Mikhail N, Lam, Carolyn S P, Langkilde, Anna Maria, Lindholm, Daniel, Bachus, Erasmus, Litwin, Sheldon E, Martinez, Felipe, Petersson, Magnus, Shah, Sanjiv J, Vaduganathan, Muthiah, Nguyen Vinh, Pham, Wilderäng, Ulrica, Solomon, Scott D, McMurray, John J V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Fast Track Congress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622300/
https://www.ncbi.nlm.nih.gov/pubmed/36029309
http://dx.doi.org/10.1093/eurheartj/ehac481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622300/
https://www.ncbi.nlm.nih.gov/pubmed/36029309
http://dx.doi.org/10.1093/eurheartj/ehac481

Ejemplares similares